CASTLE ROCK, Colo.
March 19, 2013
diagnostic company focused on obtaining FDA clearance and commercializing its rapid, protein biomarker-based appendicitis test,
, today announced it will provide a fourth quarter business update on
Tuesday, March 26, 2013
4:30 p.m. ET
. The conference call will be hosted by
, Chief Executive Officer;
, Chief Financial Officer; and
, Senior Vice President and Chief Commercial Officer.
Interested participants and investors may access the conference call by dialing 1-800-860-2442 (U.S.), 1-866-605-3852 (
) or 1-412-858-4600 (international). A live audio webcast will be accessible via the Investor Relations section of the Venaxis web site,
A telephonic replay of the call will be available for 30 days beginning at
8:00 p.m. ET
, 2013. Access numbers for this replay are 1-877-344-7529 (U.S./
) and 1-412-317-0088 (international); conference ID: 10026445. The webcast replay will remain available in the Investors Relations section of the Venaxis web site for 30 days.
About Venaxis, Inc.
Venaxis, Inc. is an
diagnostic company focused on the clinical development and commercialization of its CE-Marked rapid, protein biomarker-based appendicitis test,
. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.
is a CE Marked product in
and is being developed in the U.S. initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While FDA clearance is being sought, an initial launch for
is ongoing in select European territories. For more information, visit
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for
required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from
at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the period ended
September 30, 2012
, filed on
November 7, 2012
For Investors and Media:
Tiberend Strategic Advisors, Inc.
; (212) 375-2664
; (212) 375-2665
SOURCE Venaxis, Inc.